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ABSTRACT
Objectives: To summarise the evidence from studies
of acute kidney injury (AKI) with regard to the effect of
pre-AKI renal function and post-AKI renal function
recovery on long-term mortality and renal outcomes,
and to assess whether these factors should be taken
into account in future prognostic studies.
Design/Setting: A systematic review of observational
studies listed in Medline and EMBASE from 1990 to
October 2012.
Participants: All AKI studies in adults with data on
baseline kidney function to identify AKI; with outcomes
either stratified by pre-AKI and/or post-AKI kidney
function, or described by the timing of the outcomes.
Outcomes: Long-term mortality and worsening
chronic kidney disease (CKD).
Results: Of 7385 citations, few studies met inclusion
criteria, reported baseline kidney function and
stratified by pre-AKI or post-AKI function. For
mortality outcomes, three studies compared patients
by pre-AKI renal function and six by post-AKI
function. For CKD outcomes, two studies compared
patients by pre-AKI function and two by post-AKI
function. The presence of CKD pre-AKI (compared
with AKI alone) was associated with doubling of
mortality and a fourfold to fivefold increase in CKD
outcomes. Non-recovery of kidney function was
associated with greater mortality and CKD outcomes
in some studies, but findings were inconsistent
varying with study design. Two studies also reported
that risk of poor outcome reduced over time post-AKI.
Meta-analysis was precluded by variations in
definitions for AKI, CKD and recovery.
Conclusions: The long-term prognosis after AKI
varies depending on cause and clinical setting, but it
may also, in part, be explained by underlying pre-AKI
and post-AKI renal function rather than the AKI
episode itself. While carefully considered in clinical
practice, few studies address these factors and with
inconsistent study design. Future AKI studies
should report pre-AKI and post-AKI function
consistently as additional factors that may modify AKI
prognosis.
INTRODUCTION
Acute kidney injury (AKI) affects an esti-
mated 13–18% of hospitalised patients,1 fre-
quently under the care of specialties other
than nephrology. With the advent of an inter-
nationally agreed deﬁnition based on
changes in serum creatinine and urine
output,2 there is now increasing awareness of
the poor outcomes suffered by such patients
and this has been accompanied by an
emphasis on early detection in an effort to
improve patient safety and outcomes.1 Some
of the poor outcomes (including increased
mortality2 3 and development of chronic
kidney disease (CKD)4–6) are increasingly
described after hospital discharge, but this is
variable and factors associated with long-term
prognosis are poorly understood.1 Recent
guidelines from the National Institute for
Health and Care Excellence (NICE) call for
more studies into AKI, with non-AKI com-
parators, but without specifying which factors
should be included in study design.
Strengths and limitations of this study
▪ This systematic review followed strict inclusion,
exclusion and quality assessment criteria to
summarise the available evidence regarding the
role of pre-acute kidney injury (AKI) baseline and
post-AKI recovery of renal function in long-term
AKI outcomes.
▪ Few studies reported long-term AKI outcomes
stratified by pre-AKI and post-AKI factors.
Quantitative meta-analysis was precluded by het-
erogeneity in design of included studies.
▪ The review includes papers from Medline and
EMBASE up to October 2012. It may potentially
have missed studies published in 2013–2014 or
available in other databases.
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AKI occurs in many different situations and the
context is likely to be important when studying onset of
AKI and assessing future outcome risk. In particular,
clear knowledge of prior kidney (pre-AKI baseline) func-
tion is essential to distinguish AKI from CKD. This ‘base-
line function’ is typically a creatinine measurement prior
to hospitalisation, but may not be available. This can be
solved in clinical practice using good clinical judgement,
but in epidemiological studies patients with missing
baseline values are either assumed to be normal, esti-
mated from other results or excluded. Baseline function
is required for grading AKI severity; as a reference for
establishing if recovery is complete; and as a means of
stratifying patients with and without pre-AKI CKD. It is
intuitive that AKI in patients with advanced baseline
pre-AKI CKD could present and behave differently,7 thus
studies without baseline function are at risk of selection
bias and misclassiﬁcation of CKD as AKI.
After an episode of AKI (for instance at hospital dis-
charge or clinic review), the physician also has an opportun-
ity to consider a patient’s most recent post-AKI kidney
function. Accounting for post-AKI recovery from AKI (eg,
return of creatinine to within 20% pre-AKI creatinine2) may
assist future risk assessment. However, the timing of this
post-AKI assessment may also inﬂuence its predictive ability,
since clinical course may vary, with recovery and deterior-
ation possible and not necessarily at a constant rate.8
Thus, while there is evidence that AKI may have a
poor overall prognosis, in this systematic review we seek
to evaluate whether previous observational studies have
demonstrated the modifying contribution of pre-AKI
baseline function, post-AKI recovery and the timing of
outcomes. We also assess whether stratiﬁcation by these
factors should be necessary in future prognostic studies
and might provide valuable information to the physician
making a risk assessment.
METHODS
A systematic review of observational studies was under-
taken in accordance with guidelines for meta-analysis of
observational studies in epidemiology (MOOSE).9
Medline and EMBASE were searched from January 1990
through October 2012 using Medline subject heading
(MeSH) terms and free text for AKI (acute renal failure,
acute kidney disease, acute kidney injury, acute dialysis,
RIFLE, AKIN) and prognosis (prognosis, survival, mor-
tality, follow up, progression, chronic kidney disease,
renal replacement therapy, chronic dialysis, end-stage
kidney disease; see online supplementary material).
Reference lists of relevant studies and review articles
were also searched. There were no language restrictions.
Studies were included if AKI was deﬁned with: creatin-
ine changes within a speciﬁed time interval, hospital
episode coding for AKI, or the initiation of acute renal
replacement therapy (RRT). Studies had to report
either mortality or a CKD outcome (development of
CKD, progression of CKD severity, or end-stage kidney
disease (ESKD)). Studies were included that reported
adults (age over 18 years), had at least 50 participants
with AKI surviving to hospital discharge, and had
follow-up of at least 1 year. Studies of those with only spe-
cialised conditions (eg, cancer, chemotherapy, trans-
plantation) were excluded.
Two reviewers independently screened titles, abstracts
and full papers against the inclusion and exclusion cri-
teria. Where disagreement could not be resolved by dis-
cussion, a third author was available, but was not
required. One researcher extracted information from
the included studies into a data extraction proforma,
with conﬁrmation by a second reviewer.
Quality assessment
Six quality criteria (based on guidelines for assessing the
quality of prognostic studies10) with a speciﬁc focus on
the key areas of potential bias and heterogeneity in
studies identifying AKI and subsequent outcomes, were
used to assess the included studies (ﬁgure 1).
Analysis
Study characteristics and quality assessment information
were tabulated and described. Multiple papers from the
same study data set were presented together with ﬁnd-
ings reported from the most complete paper.
Quality criteria 1–3 limited analysis to studies that
accurately identiﬁed patients with AKI and restricted to
those who survived the acute event, without signiﬁcant
potential for misclassiﬁcation of patients with CKD. If
criteria 1–3 were not met, the study was excluded from
further analysis.
Further analysis was limited to studies that analysed
patients separately according to one of quality criteria
4–6 (analysis by pre-AKI baseline, post-AKI recovery, or
timing of outcomes).
The remaining studies, satisfying criteria 1–3 and one
of 4–6, were then summarised in two tables for mortality
Figure 1 Quality assessment
criteria (AKI, acute kidney injury;
CKD, chronic kidney disease;
eGFR, estimated glomerular
filtration rate).
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and CKD outcomes. Clinical setting of AKI was described
for each table as follows: intensive care (intensive therapy
unit (ITU): patients admitted to ITU, regardless of RRT
use), postoperative, cardiac (patients presenting follow-
ing a myocardial infarction or coronary angiogram),
unselected (studies of hospital admissions where the clin-
ical settings above did not describe all patients).
Retrospective or prospective design was also reported.
Mortality and CKD outcomes were presented separ-
ately, reporting study characteristics, population, expos-
ure, comparators, follow-up and measure of outcome.
Multivariate adjusted risk ratios for survival and CKD
outcomes were displayed graphically if available. If the
timing of outcome was considered in a study this was
indicated and described.
RESULTS
The literature search identiﬁed 7385 citations. Following
review of titles, abstracts and full texts (ﬁgure 2),
68 papers describing 61 unique studies were identiﬁed
(further details summarised in online supplementary
material). Study size varied, ranging from 61 to 82 711
individuals with follow-up from 12 to 142 months. Thirty
of 61 studies satisﬁed quality criteria 1–3, reported
either mortality or CKD outcomes (and these studies are
summarised in table 1).11–39 Notably, 28/61 studies had
insufﬁcient pre-AKI data to avoid misclassiﬁcation of
CKD as AKI. Of 30 remaining studies stratiﬁcation or
separation by exclusion of pre-AKI or post-AKI function
subgroups was performed in 16/30 mortality studies
with 14/30 not conducting separate analyses. It was also
performed in 5/30 CKD outcome studies with 25/30
not conducting separate analyses. As noted in table 2,
most studies satisﬁed quality criteria 1–3 by excluding
patient groups rather than by stratifying by pre-AKI or
post-AKI function. Only three mortality studies stratiﬁed
by pre-AKI function and six by post-AKI function. Two
CKD studies stratiﬁed by pre-AKI and two post-AKI
function. Only two mortality studies8 19 and one CKD
Figure 2 Study selection and
quality assessment (AKI, acute
kidney injury; CKD, chronic
kidney disease).
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Table 1 Description and application of quality criteria 4–6 in studies satisfying criteria 1–3
Mortality outcomes reported CKD outcomes reported For either outcome
Paper N
Clinical
setting By pre-AKI baseline
By post-AKI
recovery
By pre-AKI
function
By post-AKI
recovery Timing considered
Hoste et al27 82 ITU N N – – –
Lopes et al28 61 ITU N N – – –
Manns et al 29 66 ITU N N – – –
Schiffl and Fischer11 226 ITU CKD excluded Y – – –
Triverio et al17 95 ITU Y Y – – –
Bucaloiu et al12 1610 Unselected CKD excluded Recovered only CKD excluded Recovered only –
Hsu et al13 782 Unselected CKD only N N N –
Ishani et al18 7197 Unselected Y by code alone N Y by code alone N –
Jones et al14 719 Unselected CKD excluded Recovered only CKD excluded Recovered only –
Lafrance and
Miller19
82 711 Unselected Y Y – – Sensitivity analysis excluding
first 6 months
Lo et al30 343 Unselected N (excluded only if eGFR
<45)
N – – –
Ng et al31 262 Unselected N N – – –
Ponte et al21 177 Unselected N (Cr >1.4 excluded) Y – – –
Wald et al32 41 327 Unselected N N N N –
Gupta et al33 143 Cardiac N N – – –
Kimura et al34 81 Cardiac N N – – –
Lindsay et al35 179 Cardiac Y N – – –
Maioli et al15 167 Cardiac CKD only Y – – –
Rihal et al36 185 Cardiac N N – – –
Roghi et al37 106 Cardiac N N – – –
Brown et al22 1886 Postoperative N Y – – –
Coca et al23 6257 Postoperative N Y – – –
Ishani et al8 4053* Postoperative N N N N Changing HRs for mortality
and CKD outcomes in time
intervals
Kheterpal et al16 101 Postoperative CKD excluded N – – –
Loef et al24 145 Postoperative N Y – – –
Luckraz et al38 53 Postoperative N N – – –
Mehta et al25 2083 Postoperative N (excluded only Cr>2) Y – – –
Swaminathan et al39 1113 Postoperative N N† – – –
Van Kuijk et al26 120 Postoperative N N CKD excluded Y –
Wu et al20 4393 Postoperative Y by GFR>/<45 Y Y by GFR>/<45 Y –
*19 779 in total, 4053 of which had >50% cr rise.
†Outcomes by rate of fall of cr over a 24 h rather than a recovery variable.
–, Outcome not addressed by study; AKI, acute kidney injury; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; ITU, intensive therapy unit;; N, outcome
addressed but not per quality criterion.
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Table 2 Studies of mortality outcomes in AKI by pre-AKI and post-AKI kidney function
Mortality N
Clinical
setting Design AKI exposure Comparator Follow-up
Pre-AKI baseline
separation
Post-AKI
recovery
separation
Recovery
definition Findings
Schiffl and
Fischer11
226 ITU Cohort Acute RRT None 5 years CKD excluded Y Within 10%
baseline
Mortality 83% without recovery, 33%
with recovery
HR without vs with recovery 4.1† (no
non-AKI comparator)
Triverio
et al17
95 ITU Cohort Acute RRT None 3 years Y Y eGFR>60 Mortality 50% if baseline CKD, 29% if
eGFR <60 at discharge, 18% if no
renal impairment before or after AKI
Bucaloiu
et al12
1610 Unselected Cohort Cr rise >50% No AKI 3.3 years* CKD excluded Recovered only Within 10%
baseline
HR Mortality 1.48†
Hsu et al13 782 Unselected Cohort Acute RRT CKD with no
RRT
4 years CKD only
(eGFR<45)
N – HR composite end point of ESKD or
mortality 1.3†
Ishani
et al18
7197 Unselected Cohort Code No AKI or
CKD code
2 years Y by code alone N – HR mortality vs no AKI or CKD
AKI and CKD 3.24†, AKI 2.48†, CKD
1.45†
Jones
et al14
719 Unselected Cohort Code No AKI 2.5 years* CKD excluded Recovered only Within 10%
baseline
HR Mortality 1.08
Lafrance
et al19
82 711 Unselected Cohort Cr rise >50% No AKI 2.34 years* Y Recovered only
in a
subanalysis
Within 10%
baseline
HR mortality for AKI vs no AKI in
90-day survivors 1.41†
Subgroup of 6-month survivors 1.13†
Subgroup with recovery 1.47†
Ponte
et al21
177 Unselected Cohort Cr rise
from<1.4 mg/dL
to >2
None 7.2 years* CKD excluded
(Cr >1.4 mg/dL)
Y Cr<1.4 mg/dL 10-year mortality 40% with recovery,
57% without recovery
Lindsay
et al35
179 Cardiac Cohort Cr rise 50%
from<1.2 mg/dL
No AKI 1 year CKD excluded
(cr >1.2 mg/dL)
N – 1-year mortality 9.5% AKI, 2.7%
no-AKI
Maioli
et al15
167 Cardiac Cohort Cr rise (0.5 mg/
dL by 3 days)
No AKI 3.8 years* CKD only (eGFR
<60)
Y Within 25%
baseline at
3 months
HR mortality for AKI with
recovery1.3†, without recovery 2.3†
Brown
et al22
1886 Postoperative Cohort Cr rise
0.3 mg/dL or
50%
No AKI 2.6 years* N Y Number of days
AKI definition met
HR mortality for AKI vs no AKI by AKI
duration
1–2 days 1.51†, 3–6 days 1.74†,
>7 days 3.45†, persistent 5.75†
Coca et al23 6257 Postoperative Cohort Cr rise
0.3 mg/dL or
50%
No AKI 3.8 years* N Y Number of days
AKI definition met
HR mortality for AKI vs no AKI by AKI
duration
<2 days 1.15†, 3–6 days 1.5†,
>7 days any duration with RRT 2.10†
Kheterpal
et al16
101 Postoperative Cohort Cr clearance fall
to<50
No AKI 1 year CKD excluded N – 1-year mortality 12% AKI, 9% no AKI
Loef et al24 145 Postoperative Cohort Cr rise 25% No AKI 100 months N Y “Improved to or
below the
preoperative level”
HR mortality for AKI 1.63†, AKI with
recovery 1.66†, AKI without recovery
1.72†, non-recovery vs recovery 1.22
(not significant)
Continued
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outcome study8 addressed whether the risk of outcomes
changed with increasing time from AKI.
Among these studies, deﬁnitions varied: AKI was
deﬁned by acute RRT,13 different thresholds for creatinine
rise,15 23–26 or hospital episode code.14 18 CKD was deﬁned
by hospital codes,18 low estimated glomerular ﬁltration
rate (eGFR) for CKD cut-off (<45 mL/min/1.73 m2)13 20
conventional eGFR for CKD (<60 mL/min/1.73 m2),15
varying thresholds based on serum creatinine21 35 or hos-
pital episode code.18 Deﬁnitions of renal recovery also
varied: with deﬁnitions of its timing ranging from 3 days26
to 3 months;15 and its extent from within 50% of baseline20
to within 10% of baseline,14 or below a pre-AKI value.24
Mortality findings
There were 16 mortality studies (table 2). Follow-up
ranged from 1 to 7 years and mortality up to 83% for
patients with AKI at 5 years. AKI was associated with
increased mortality in all but one study14 regardless of
pre-AKI baseline (HR 1.08 to 4.59; ﬁgure 3) or recovery
of renal function (HR 1.08 to 5.75; ﬁgure 4). Five
studies did not report non-AKI comparators11 17 21 or
risk ratios.16 35
Of the three studies stratiﬁed by pre-AKI baseline
function, in two the overall prognosis was worse in
patients with AKI with prior CKD with doubling of HRs
with respect to a non-AKI non-CKD comparator.15 20
However, in a third study, where comparators were also
stratiﬁed by eGFR, the independent mortality risk from
AKI diminished with advancing CKD.19 Six studies com-
pared mortality stratifying either by post-AKI recovery
(four studies)15 20 24 25 or by AKI duration (two
studies).22 23 All but one15 were postoperative studies
with different thresholds for deﬁning recovery. Risk
from incomplete recovery varied from minimal with
overlapping CIs15 20 24 25 to greater than double when
AKI lasted more than 1 week.22 23 Only one study com-
bined stratiﬁcation by pre-AKI baseline and by post-AKI
recovery (deﬁning recovery to 50% baseline, CKD as
eGFR<45 mL/min/1.73 m2) with non-recovery as well as
baseline CKD adding to mortality risk.20
CKD outcomes
In ﬁve studies, there was marked variation in CKD out-
comes following AKI (HR 1.91 to 213) depending on
pre-AKI baseline and post-AKI recovery (table 3 and
ﬁgure 5).12 14 18 20 26 In the two studies stratifying by
pre-AKI function, AKI with baseline CKD was associated
with a substantially greater (fourfold to ﬁvefold) risk of
ESKD than AKI in cases without prior CKD18 20 although
notably one study deﬁned CKD at eGFR<45 mL/min/
1.73m2 20 and the other by a hospital code.18 The two
studies stratifying by post-AKI function had different ﬁnd-
ings. In one postoperative study26 there was no associ-
ation between non-recovery post-AKI (vs patients with
recovery) and additional CKD progression, when recov-
ery was measured at day three,26 but association was sub-
stantial (5–10-fold) in the other study where recovery was
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deﬁned at hospital discharge.20 Again only one study
stratiﬁed by both baseline and recovery, ﬁnding both
associated with poorer prognosis.20
Timing of outcomes
Two studies considered whether HRs changed over time
following the AKI episode.8 19 Lafrance et al,19 per-
formed a sensitivity analysis of their study of AKI survi-
vors and mortality, limiting analysis from 90-day to
6-month AKI survivors. The mortality HR (AKI vs
non-AKI) fell from 1.41 (1.39 to 1.43) in 90-day survivors
to 1.13 (1.11 to 1.14) in 6-month survivors.19 Ishani et al8
reported changes in HR of mortality and CKD outcomes
from AKI (vs no AKI) when dividing follow-up into
6-month time discrete intervals. For both mortality and
CKD outcomes, greatest relative risk (vs non-AKI) was in
the ﬁrst 6 months, with marked attenuation of risk (but
still statistically signiﬁcant) from 1 year.8 While recognis-
ing that risk may not be constant, the study also did not
consider the importance of stratifying patients by
pre-AKI baseline or post-AKI recovery.
DISCUSSION
The introduction of a global deﬁnition for AKI has led
to growing interest in the high incidence and poor out-
comes. In this review of 7385 citations, there were only
30 studies that met the initial quality criteria for select-
ing patients with AKI with sufﬁcient efforts to avoid mis-
classifying CKD. Of these studies only three mortality
studies stratiﬁed by pre-AKI, six by post-AKI function,
two CKD outcome studies by pre-AKI and two by post
AKI function. Only one study considered both pre-AKI
and post-AKI function. Only two studies considered the
change in risk over time from AKI.
As with two previous reviews, we note that AKI is asso-
ciated with overall poorer mortality and CKD outcomes,3 5
but with substantial variation in the magnitude of risk. We
were transparent about the variation in deﬁnitions and
clinical setting and identiﬁed heterogeneity as a problem
with the design of AKI studies to date. The two previous
reviews included studies with incomplete or estimated data
on baseline kidney function,3 5 but in studies with available
data we found that outcomes were modulated by pre-AKI
baseline and post-AKI renal recovery. Unfortunately, these
studies varied in deﬁnitions for AKI, recovery and
follow-up preventing pooled meta-analysis. While protein-
uria and oliguria may also be important factors, research
on their association with long-term prognosis is sparse and
we therefore focused on the course of serum creatinine
prior and subsequent to the AKI episode.
Pre-AKI baseline CKD was associated with doubling of
mortality outcomes and fourfold to ﬁvefold increased risk
of CKD outcomes compared to patients with non-AKI
non-CKD. Unfortunately, only one study chose CKD com-
parators for patients with AKI at each level of pre-AKI func-
tion, ﬁnding that the additional risk from AKI diminished
in those already at high risk due to advanced baseline
CKD.19 It is likely the mortality and ESKD risk in advanced
CKD is already high and less inﬂuenced by AKI.
Figure 3 Mortality—by pre-AKI baseline (AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; w/o rec, without recovery; with rec, with recovery).
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Non-recovery of kidney function was associated with
greater mortality and CKD outcomes in some studies,
but the ﬁnding was inconsistent and dependent on
study design. Studies with a less stringent threshold20
and later point of assessment15 showed a poorer progno-
sis with non-recovery, highlighting the signiﬁcance of
arbitrary thresholds in study design. We also note a
further study outside the time period in this review
reporting a cohort with poorer outcomes with non-
recovery after AKI, in line with our overall ﬁndings.40
Increased risk of poor outcomes following AKI may be
greatest early post-AKI, and therefore the timing of clin-
ical assessment is important. Despite this, most studies
followed a ‘proportional hazards’ assumption (ie, that
the relative risk of AKI vs non-AKI comparator was con-
stant over time), but this may not hold. Only two studies
considered the timing of assessment post-AKI and found
that additional risk of mortality as well as renal progres-
sion may diminish over time,8 19 but neither combined
this with adjustment nor stratiﬁcation by post-AKI recov-
ery. Both factors are required to assess if the rate of CKD
progression is more rapid in AKI than non-AKI (but
baseline CKD) comparators with equal kidney function
at the time of hospital discharge. Thus, understanding
of how mortality and renal progression risks change over
time remains inadequately addressed.
Overall while our ﬁndings broadly agree with previous
reviews,3 5 we found that some of the variation in AKI
prognosis may be explained by pre-AKI CKD and
post-AKI non-recovery which both lead to a poorer prog-
nosis. This is of great relevance given that these factors
were infrequently addressed by stratiﬁcation, and 28/61
studies had insufﬁcient pre-AKI data to minimise mis-
classiﬁcation between CKD and AKI. The relationships
are complex with diminishing additional risk with advan-
cing pre-AKI CKD. We also noted a non-linear clinical
post-AKI course, with risk prediction dependent on the
time point at which risk is assessed, necessitating ﬁxed
follow-up points to prevent overestimation of risk in a
cohort with shorter follow-up. Importantly, few studies
assessed these factors, using different deﬁnitions, and
with only one study assessing both pre-AKI and post-AKI
factors. This review included studies up to October 2012
and in the near future it is likely that AKI registries with
additional routine outcome data will become available.
Therefore there is now an opportunity to ensure that a
concordance exists in deﬁnitions and reporting of
future AKI studies before this review is revisited.
The NICE guidelines call for further studies of long-
term AKI prognosis but without speciﬁc detail on which
factors should be included. We suggest that future
studies should adopt consistent deﬁnitions, incorporate
Figure 4 Mortality—by post AKI recovery (AKI, acute kidney injury; CKD, chronic kidney disease; w/o rec, without recovery;
with rec, with recovery).
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Table 3 Studies of CKD outcomes in AKI by pre-AKI and post-AKI kidney function
Progression N
Clinical
setting Design AKI exposure Comparator Follow-up
Pre-AKI
baseline
separation
Post-AKI
recovery
separation
Recovery definition
(discharge unless
otherwise stated) Findings
Bucaloiu et al12 1610 Unselected Cohort Cr rise >50% No AKI 3.3 years* CKD excluded Recovered only Within 10% baseline Development of new CKD stage
3/1000 person-year 28.1 AKI vs
13.1 no AKI (HR 1.91†)
Ishani et al18 7197 Unselected Cohort Code No AKI or
CKD code
2 years Y by code
alone
N – ESKD/1000 person-year (HR vs
no code)
AKI and CKD 79.45 (HR 41.2†)
AKI 24.52 (HR 13†)
CKD only 19.88 (HR 8.43†)
No Code 2.08 (reference)
Jones et al14 719 Unselected Cohort Code No AKI 2.5 years* CKD excluded Recovered only Within 10% Baseline HR for new CKD stage 3 (15%
of AKI vs 3% of no AKI patients)
3.82†
van Kuijk et al26 493 Postoperative Cohort 10% Cr change
by day 2 post-op
No AKI 5 years* CKD excluded Y Within 10% baseline at
day 3
Development of new CKD
11% if no AKI, 32% if AKI
recovered (HR 3.4†), 36% if AKI
without recovery (HR3.6†)
Wu et al20 4393 Postoperative Cohort Cr rise (RIFLE, or
50% rise if
previous CKD)
No AKI and
no CKD
4.76 years* Y by GFR>/<45 Y Within 50% baseline Development of ESKD (vs no
code)
AKI only 4.64†, CKD only
40.86†, AKI and CKD 91.69†
Stratified by recovery
AKI+CKD+without recovery
212.73†
AKI+CKD+recovery 74.07†
AKI only+without recovery
60.95†
AKI only+recovery 4.5†
*Mean/median.
†Statistically significant p<0.05.
–, Outcome not addressed by study; AKI, acute kidney injury; CKD, chronic kidney disease; Cr, serum creatinine; eGFR, estimated glomerular filtration rate; ESKD, end-stage renal disease
(dialysis >90 days); ITU, intensive therapy unit; N, outcome addressed but not per quality criterion; RRT, renal replacement therapy.
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baseline and recovery function and consider the timing
of outcomes during follow-up. We therefore suggest
that future long-term prognostic studies should adopt
the KDIGO deﬁnition for identifying and stratifying
AKI,41 the KDIGO CKD stages for stratifying AKI and
non-AKI comparator groups by pre-AKI eGFR,42 the
UK Renal Association deﬁnition of renal recovery for
stratifying recovery (within 20% of baseline)2 and ﬁxed
interim points for establishing recovery (7, 30 and
90 days) and excluding early outcomes (up to 30, 90
and 180 days).
CONCLUSION
AKI has a poor, but variable prognosis inﬂuenced by
clinical setting, underlying cause and comorbidity.
There is a recognised need to understand which patients
are at greater long-term risk and when AKI may carry
additional risk beyond the underlying illness. In this
review, pre-AKI CKD was associated with doubling of
mortality outcomes and a fourfold to ﬁvefold increase in
renal outcomes. Non-recovery of kidney function may
also affect prognosis, but the magnitude depended on
both recovery deﬁnition and the timing of assessment.
These factors are already considered by physicians in
clinical practice, but unfortunately we found that few
prognostic studies have addressed them. The heterogen-
eity of studies and accompanying lack of a clear consist-
ent pattern of effect limit their clinical interpretation. As
pre-AKI and post-AKI renal function may inﬂuence clin-
ical practice, we suggest that consistent reporting of
these factors is needed in future prognostic studies to
establish how they modify AKI prognosis. This will
inform the clinician as well as future research.
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The reference numbers are correctly displayed throughout the manuscript and all the
tables. However, the ﬁgures were published with incorrect reference numbers. The ﬁndings
of the study and data presented are all correct, but the ﬁgures could be misleading/confus-
ing in their current form. The correct ﬁgures are below.
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Figure 3 Mortality—by pre-AKI baseline (AKI, acute kidney injury; CKD, chronic kidney disease;
eGFR, estimated glomerular filtration rate; w/o rec, without recovery; with rec, with recovery).
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Figure 4 Mortality—by post AKI recovery (AKI, acute kidney injury; CKD, chronic kidney disease; w/o rec, without recovery;
with rec, with recovery).
Figure 5 CKD outcomes (w/o rec, without recovery; with rec, with recovery; ESKD, end-stage kidney disease).
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